469 related articles for article (PubMed ID: 24497537)
21. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM; Frieri C; Urciuoli E; Marano L
Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
[TBL] [Abstract][Full Text] [Related]
22. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
[TBL] [Abstract][Full Text] [Related]
23. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors.
Mastellos DC; Ricklin D; Sfyroera G; Sahu A
Clin Immunol; 2022 Feb; 235():108785. PubMed ID: 34147650
[TBL] [Abstract][Full Text] [Related]
24. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
[TBL] [Abstract][Full Text] [Related]
25. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
26. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Marotta S
Am J Hematol; 2018 Aug; 93(4):564-577. PubMed ID: 29314145
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
28. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
[TBL] [Abstract][Full Text] [Related]
29. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
30. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Xu B
Clin Exp Med; 2023 Jul; 23(3):717-726. PubMed ID: 35441351
[TBL] [Abstract][Full Text] [Related]
31. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
32. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
[TBL] [Abstract][Full Text] [Related]
33. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
34. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.
Risitano AM
Transl Med UniSa; 2014 Jan; 8():43-52. PubMed ID: 24778997
[TBL] [Abstract][Full Text] [Related]
35. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.
DeZern AE; Uknis M; Yuan X; Mukhina GL; Varela J; Saye J; Pu J; Brodsky RA
Exp Hematol; 2014 Oct; 42(10):857-61.e1. PubMed ID: 25034232
[TBL] [Abstract][Full Text] [Related]
36. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Mastellos DC; Reis ES; Yancopoulou D; Risitano AM; Lambris JD
Semin Hematol; 2018 Jul; 55(3):167-175. PubMed ID: 30032754
[TBL] [Abstract][Full Text] [Related]
37. Pegcetacoplan: First Approval.
Hoy SM
Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834
[TBL] [Abstract][Full Text] [Related]
38. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
[TBL] [Abstract][Full Text] [Related]
39. Compstatins: the dawn of clinical C3-targeted complement inhibition.
Lamers C; Mastellos DC; Ricklin D; Lambris JD
Trends Pharmacol Sci; 2022 Aug; 43(8):629-640. PubMed ID: 35090732
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Kulasekararaj AG; Kuter DJ; Griffin M; Weitz IC; Röth A
Blood Rev; 2023 May; 59():101041. PubMed ID: 36732204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
